Case Report

Sleep is associated with reduction of epileptiform discharges in benign adult familial myoclonus epilepsy

Takefumi Hitomi a,b,c,*, Morito Inouchi b,d, Hirofumi Takeyama b,d, Katsuya Kobayashi b, Shamima Sultana b, Takeshi Inoue b, Yuko Nakayama c, Akihiro Shimotake b,d, Masao Matsuhashi f, Riki Matsumoto b,e, Kazuo Chin d, Ryosuke Takahashi b, Akio Ikeda e

a Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
b Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
c Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
d Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
e Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
f Department of Respiratory Care and Sleep Control Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
e Department of Clinical Laboratory Medicine, Kyoto University School of Medicine, Department of Clinical Laboratory Medicine, Kyoto University School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.

* Corresponding author at: Department of Neurology, Kyoto University Graduate School of Medicine, Department of Clinical Laboratory Medicine, Kyoto University School of Medicine, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan.
E-mail address: hitomi46@kphp.kyoto-u.ac.jp (T. Hitomi).

ARTICLE INFO

Article history:
Received 7 June 2018
Received in revised form 20 September 2018
Accepted 27 September 2018
Available online 16 October 2018

Keywords:
Benign adult familial myoclonus epilepsy (BAFME)
Epileptiform discharges
Effects of sleep modification on cortical irritability

ABSTRACT

To clarify the effects of sleep on cortical irritability in benign adult familial myoclonus epilepsy (BAFME), we retrospectively compared epileptiform discharges of electroencephalographies (EEGs) between awake and sleep periods in 5 patients (mean age: 49.6 ± 20.3 years). We also analyzed polysomnography (PSG) of 1 patient. Epileptiform discharges were significantly more frequent during the wake period (1.3 ± 1.2/min) than those during light sleep stages (0.02 ± 0.04/min) (P < 0.05). Regarding PSG analysis, epileptiform discharges were also reduced during all sleep stages compared to those during awake periods. Our study suggests a relative reduction in cortical irritability during sleep in BAFME.

© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Benign adult familial myoclonus epilepsy (BAFME) shows as a clear autosomal dominant trait with high penetration and its major two symptoms are cortical tremor mimicking essential tremor and infrequent generalized seizures. BAFME has been reported under various designations in Japan from early 1990s [1,2], whereas familial cortical tremor, myoclonus, and epilepsy (ADCME) [4] came from Europe after the new millennium. Despite different terminologies, Japanese BAFME and European ADCME share the features of core clinical symptoms and electrophysiologically proven cortical reflex myoclonus [3]. As for a recent genetic study, a novel in-frame insertion/deletion in the 2-adrenergic receptor subtype B was found to be associated with ADCME [5] and δ-catenin was proposed as the causal gene in FCMTE [6]. Furthermore, abnormal expansions of TTTCAT and TTATA repeats were reported in Japanese BAFME [7].

Previous electroencephalography (EEG) studies in Japanese BAFME showed generalized- spike and- wave complexes with photosensitivity [2]. Additionally, we recently showed that the frequency of the posterior dominant rhythm of BAFME was significantly slower than the age-matched control subjects regardless of anti-seizure drug usage, which suggests that Japanese patients with BAFME have mild diffuse brain dysfunction [8]. These EEG findings mainly focused on the awake period, but did not investigate the sleep period. Epileptiform discharges and epileptic seizures usually increase during sleep [9], and thus sleep is generally considered a precipitating factor of cortical irritability in epilepsy. However, no studies have been conducted to address the change in cortical irritability during sleep in BAFME. The present study analyzed epileptiform discharges in BAFME to determine whether cortical irritability as indicated by epileptiform discharges was modified by sleep.

Abbreviations: ADCME, autosomal dominant cortical tremor, myoclonus, and epilepsy; BAFME, benign adult familial myoclonus epilepsy; EEG, electroencephalography; EMG, electromyography; FCMTE, familial cortical myoclonic tremor with epilepsy; nCPAP, nasal continuous positive airway pressure; PSG, polysomnography; REM, rapid eye movement; ULD, Unverricht-Lundborg disease.

https://doi.org/10.1016/j.ebcr.2018.09.010
2213-3232/© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Material and methods

2.1. Conventional EEG analysis

We retrospectively analyzed 31 EEGs of 12 patients with a clinical diagnosis of BAFME in whom EEG was taken from 2008 to 2015 in our institute. Some of the patients were reported elsewhere for completely different purposes [8,10–12]. The electroclinical diagnostic criteria of BAFME are the same as in our recent studies [8,10–12], and the details are described elsewhere [10]. In addition, 10 out of 12 patients showed genetic abnormality [7], but remaining 2 patients did not undergo genetic testing. As for medications, 2 patients had clonazepam, 1 patient had piracetam, 1 patient had clonazepam and levetiracetam, and remaining 1 patient had none (Table 1).

Routine EEG with scalp electrodes was conventionally recorded according to the International 10–20 system. Routine EEG was recorded at least 30 min during daytime. Electrooculogram, electrocardiogram and electromyogram (EMG) from wrist extensor muscle were also recorded. The bandpass filter was set to 0.53–120 Hz for visual inspection. We checked 3 recording conditions and excluded the conventional EEGs from further analysis if they were not suitable for this study. First, we excluded 6 EEGs because they showed less than 5 epileptiform discharges throughout the EEG recording. Second, we excluded 18 EEGs because they showed an awake or sleep EEG of less than 10% of the total EEG recording. Third, we excluded 1 EEG with abundant artifacts. We finally analyzed 6 EEGs in 5 BAFME patients (5 women, age 49.6 ± 20.3 years) (Table 1), and 4 out of 5 patients showed genetic abnormality [7], but remaining 1 patient (Patient 5) did not undergo gene analysis.

Table 1. Patient profiles.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Cortical tremor onset age</th>
<th>Generalized seizure onset age</th>
<th>Anti-seizure drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt 1</td>
<td>73</td>
<td>50</td>
<td>62</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>Pt 2</td>
<td>40</td>
<td>20</td>
<td>28</td>
<td>Clonazepam</td>
</tr>
<tr>
<td>Pt 3</td>
<td>30</td>
<td>19</td>
<td>24</td>
<td>Piracetam</td>
</tr>
<tr>
<td>Pt 4</td>
<td>35</td>
<td>27</td>
<td>35</td>
<td>None</td>
</tr>
<tr>
<td>Pt 5</td>
<td>70</td>
<td>48</td>
<td>48</td>
<td>Clonazepam, Levetiracetam</td>
</tr>
</tbody>
</table>

Each sleep stage [awake: W, Stage I and II (light sleep); III and IV (slow-wave sleep); and REM (rapid eye movement)] was defined by a board-certified electroencephalographer (T.H) every 30 s based on the standard sleep staging criteria established by Rechtschaffen and Kales [13], although surface EMG was recorded using the wrist extensor muscle instead of the chin muscle. After sleep staging, we counted the epileptiform discharges for each sleep stage and compared the number and frequency of epileptiform discharges for each sleep stage using the Wilcoxon signed ranks test because only awake (31.3 ± 9.1 min) and Stage I and II (light sleep) (19.2 ± 14.9 min) were observed. P < 0.05 was considered statistically significant.

2.2. Polysomnography (PSG) analysis

One BAFME patient (59-year-old female) was incidentally suspected as having obstructive sleep apnea and underwent PSG before and after nasal continuous positive airway pressure (nCPAP) therapy. The patient also showed genetic abnormality [7]. Each sleep stage was also defined based on standard sleep staging criteria [13]. We counted the epileptiform discharges during each awake and sleep stage and then compared the number and frequency of epileptiform discharges during the awake and sleep stages.

3. Results

3.1. Conventional EEG analysis

Five BAFME patients showed generalized spikes maximal in the posterior hemisphere during the awake period (42.6 ± 37.9/record) (Fig. 1A, Table 2), however, these epileptiform discharges nearly disappeared during light sleep (0.6 ± 1.3/record; p < 0.05) (Fig. 1B, Table 2). With respect to the frequency recorded as number of events/min, epileptiform discharges also significantly decreased during light sleep (0.02 ± 0.05) compared to the awake stages (1.3 ± 1.3; p < 0.05) (Table 2).

3.2. PSG analysis

PSG before nCPAP therapy showed severe obstructive sleep apnea (apnea hypopnea index: 39.2). Sleep stages were classified into Awake (105 min), Stage I and II (147 min), III and IV (0 min), and
REM (27.5 min). There were frequent epileptiform discharges during the awake period (106), however, the number of epileptiform discharges clearly decreased during Stages I and II (5) and the REM stage (2) (Table 3). The frequency of epileptiform discharges also showed the same tendency: awake period: 1.01, Stage I and II: 0.03, and stage REM: 0.07 (Table 3). PSG after nCPAP therapy showed a normalized apnea hypopnea index (4.0). The sleep stages were classified into Awake (88 min), Stage I and II (228 min), Stage III and IV (14 min), and stage REM (0 min). Some epileptiform discharges occurred during the awake period (7), likely due to a reduction in cortical irritability through nCPAP therapy [14], and no epileptiform discharges were observed during Stage I, II, III, or IV (Table 3). The frequency of epileptiform discharges (number/min) also showed the same tendency: awake period: 0.08, Stage I and II: 0, and stage III and IV: 0 (Table 3).

4. Discussion

Our study showed a clear reduction in epileptiform discharges during sleep regardless of sleep stage in patients with BAFME. This result contrasted with our expectations because epileptiform discharges, as known from a previous study, usually increase during the sleep period in most focal and generalized epilepsies [9]. Notably, Unverricht-Lundborg disease (ULD), which is a type of progressive myoclonus epilepsy, showed a reduction in paroxysmal abnormalities during non-REM and REM sleep [15]. Additionally, ULD showed generalized spikes with predominance in the posterior region [16], which is consistent with the distribution of generalized spikes in BAFME as shown in Fig. 1A. Taken all together, ULD and BAFME showed a similar pathological mechanism of cortical irritability in terms of spatial distribution and the response to state changes.

There is a hypothesis regarding the reduction of epileptiform discharges during the sleep period in BAFME. First, generalized epilepsy usually showed diffuse epileptiform discharges with frontal predominance. Additionally, frontal lobe epilepsy also showed focal epileptiform discharges in the frontal region, which often produces epileptic seizures while asleep [9]. These findings were supported by emphasized high gamma activity and neuronal synchrony during sleep in the frontal lobe compared to other lobes [17]. In contrast, occipital lobe epilepsy tended to occur while awake [18]. In addition, BAFME and ULD show diffuse epileptiform discharges but its predominance was sometimes in the occipital area, and both also could show fragmented occipital spikes as well. Thus, BAFME and ULD may share the similar tendency to occipital lobe epilepsy at least partly for the effects of sleep on the cortical irritability of the brain.

BAFME was considered to have a benign clinical course, unlike progressive myoclonus epilepsy. However, we recently demonstrated an increase in the amplitude of somatosensory evoked potential with age [10], clinical anticipation [12] and its exaggeration by maternal transmission [11], and a mild slowing of the posterior dominant rhythm of EEG [8] in BAFME. Based on our recent observations, we now believe that BAFME is not completely benign but has a slow progressive pathophysiology that occurs with age. Therefore, the findings in this study were consistent with our recent hypothesis because BAFME showed a similar degree of cortical irritability in its spatial distribution and its response to state change in ULD, which is one of the milder forms of progressive myoclonus epilepsy. The functional change during sleep periods may provide novel insights into the pathophysiology of BAFME. However, the pathogenesis of BAFME remains unknown, although it was shown that abnormal expansion of TTTC and TTTC repeats in BAFME [7] and abnormal expansion of dodecamer repeats in ULD.

Table 2
Summary of the electroencephalography analysis.

<table>
<thead>
<tr>
<th>Sleep staging (min)</th>
<th>Number of epileptiform discharges</th>
<th>Frequency of epileptiform discharges (number/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awake</td>
<td>SI and II</td>
<td>Awake</td>
</tr>
<tr>
<td>Pt 1</td>
<td>40</td>
<td>19</td>
</tr>
<tr>
<td>Pt 2</td>
<td>22</td>
<td>39</td>
</tr>
<tr>
<td>Pt 3</td>
<td>42</td>
<td>28</td>
</tr>
<tr>
<td>Pt 4</td>
<td>27</td>
<td>6</td>
</tr>
<tr>
<td>Pt 5</td>
<td>26</td>
<td>4</td>
</tr>
<tr>
<td>Mean</td>
<td>31.3</td>
<td>19.2</td>
</tr>
<tr>
<td>SD</td>
<td>9.1</td>
<td>14.9</td>
</tr>
</tbody>
</table>

SI and II: sleep stage I and II. *P < 0.05 (Wilcoxon signed rank test).

Table 3
Summary of the polysomnography analysis.

<table>
<thead>
<tr>
<th>Number of epileptiform discharges during awake and sleep period</th>
<th>Frequency of epileptiform discharges during awake and sleep period (number/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awake</td>
<td>SI and II</td>
</tr>
<tr>
<td>PSG (pre nCPAP)</td>
<td>106</td>
</tr>
<tr>
<td>AH1: 39.2</td>
<td></td>
</tr>
<tr>
<td>PSG (post nCPAP)</td>
<td>7</td>
</tr>
<tr>
<td>AH1: 4.0</td>
<td></td>
</tr>
</tbody>
</table>

This study has a number of limitations. First, the number of studied patients in conventional EEG analysis was relatively small. More than half of the EEG data were eliminated because of the strict criteria of this study. However, we showed statistically significant differences in epileptiform discharges in this study. Second, only 1 patient underwent a PSG study, and thus we could not show statistically significant differences between the slow wave sleep and REM periods, notably, epileptiform discharge consistently decreased during slow wave and REM sleep as well as the light sleep periods. Third, sleep staging was performed based on the information with conventional EEG recordings; however, sleep staging in this study appears to be accurate because only the awake and Stage I and II (light sleep) periods were observed. This likely occurred because the routine EEG was recorded only during daytime.

5. Conclusion

Our retrospective EEG and PSG analysis showed a clear reduction of the epileptiform discharges during sleep in BAFME, which suggests a reduction in cortical irritability during sleep in BAFME. Since ULD, a type of progressive myoclonus epilepsy, also demonstrates a similar degree of cortical irritability represented by epileptiform discharges, BAFME and ULD may share a similar phenomenological mechanism.

Author’s contributions

All authors gave substantial contribution to the submitted manuscript. Takefumi Hitomi: conception, data collection, statistical analysis, manuscript draft and revision. Morito Inouchi, Katsuya Kobayashi: data collection and technical advice. Shamima Sultana, Takeshi Inoue, Yuko Nakayama, Akihiro Shimotake, Masao Matsuhashi, Riki Matsumoto: data collection and technical advice. Akio Ikeda: data analysis and manuscript revision.

Ethical publication statement

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure of conflicts of interest

Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine is an endowment department supported with grants from GlaxoSmithKline K.K., NIHON KOHDEN CORPORATION, Otsuka Pharmaceutical Co., and UCB Japan Co., Ltd.

Acknowledgements

This study was supported by the Kyoto University Research Fund for Senior Scientists and by a Grant-in-Aid for Scientific Research on Innovative Areas (Non-linear Neuro-oscillology: Towards Integrative Understanding of Human Nature) KAKENHI Grant Number 15H05874, a Grant-in-Aid for Scientific Research (C), KAKENHI Grant Number 17K09798) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

References